Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Could Electromagnetic Treatment Reverse Memory Loss in Alzheimer’s Disease Patients?

XTALKS VITALS NEWS

Alzheimer's Disease

Preclinical data on the NeuroEM 1000 medical device showed that the technology was able to prevent – and even reverse – memory loss in mice models of Alzheimer’s disease.

Share this!

December 7, 2016 | by Sarah Hand, M.Sc.

A medical device which provides transcranial electromagnetic treatment (TEMT) to the brain, is being investigated in a new clinical trial involving patients with Alzheimer’s disease. The device – known as the NeuroEM 1000 – was developed by medical device company, NeuroEM Therapeutics.

The Phase I clinical trial will be conducted over a 2-month period by researchers at Banner Sun Health Research Institute and Banner Alzheimer's Institute, both in Phoenix, Arizona. Preclinical data on the NeuroEM 1000 medical device showed that the technology was able to prevent – and even reverse – memory loss in mice models of Alzheimer’s disease.

“We are very pleased to have two of the country's most notable and trusted Alzheimer's research institutes performing this first-of-its-kind clinical trial,” said Dr. Gary Arendash, President and CEO of NeuroEM Therapeutics. “Although the Phase I trial is primarily to investigate safety of the TEMT head device, a number of measures have been included in the trial's design that could provide evidence of therapeutic efficacy.”



According to NeuroEM Therapeutics, the TEMT is thought to disrupt the amyloid protein aggregates in the brain which are associated with Alzheimer’s pathology. The technology also stimulates mitochondrial functioning to increase energy production in brain cells damaged by Alzheimer’s.

Patients enrolled in the clinical trial of the NeuroEM 1000 device will receive TEMT treatments administered by their caregiver. As the medical device only needs to be worn twice per day for one-hour treatments, Alzheimer’s patients participating in the study do not need to travel to a clinical trial site in order to complete their therapy.

Drug development in the Alzheimer’s space has been slow and fraught with clinical failures. NeuroEM Therapeutics believes that neuromodulatory disease interventions could be more successful in treating the neurodegenerative disorder.

The TEMT technology was developed by Arendash and his colleagues at the Florida Alzheimer's Disease Research Center. The study coordinators expect that the results of the Phase I Alzheimer’s clinical trial will be released in Spring 2018.


Keywords: Alzheimer's Disease, Medical Device, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.